Over the past decades, prognosis of advanced stage epithelial ovarian cancer remains very poor, despite the development of new chemotherapeutic drugs, as well as molecular targeted agents. Late presentation and frequent chemoresistance account for the poor prognosis. Emerging studies have shown that many genetic changes, especially p53 mutation, are associated with the chemoresistance. However, recent failure of the clinical trials using p53 gene-therapy makes researchers discuss the possible reasons for the failure. Epigenetic changes are considered one of the substantial reasons. Successful restoration of the aberrant epigenetic changes may be a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. Herein, we will summarize the rationale for epigenetic therapy of cancer and current status of epigenetic studies in relation to chemoresistance in epithelial ovarian cancer. (J Cancer Prev 2013;18:227-234) 
INTRODUCTION
Ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of cancer death in women in the US. 1 Since there is no effective screening tool and the lack of early presenting symptoms, patients are typically diagnosed late, when complete surgical cytoreduction is not possible. In addition to the late diagnosis, over 70% of high recurrence rate, especially for platinum-resistant tumor, keeps the 5-year survival rate for the patients with advanced epithelial ovarian cancer (EOC) below 30%. 1 Despite enormous efforts to develop effective anti-cancer drugs, there was little change in the poor outcome of EOC over the past decades. Therefore, the development of a novel therapeutic strategy is imperative for improving the survival of women with EOC.
P53 GENE THERAPY AS A DISAPPOINTING MASTER PLAN 1. P53 and ovarian cancer
A p53 is a master regulator of the apoptotic pathway and coordinates the programmed cell death at many levels through numerous mechanisms. Apoptotic pathways are considered to contribute to the cytotoxic action of several chemotherapeutic drugs including cisplatin, which is most commonly used in EOC. Loss or mutation of p53 has been reported to be causally associated with chemoresistance in EOC. [2] [3] [4] Mutation and loss of TP53 function is one of the most frequent genetic abnormalities in ovarian carcinoma and is observed in 60-80% of both sporadic and familial cases. 5 Furthermore, TP53 mutation and consequent overexpression are observed more frequently in advancedstage than in early-stage and are associated with the poor survival. 6, 7 It is possibly not only due to more aggressive phenotype but also due to the resistance to chemotherapy-induced apoptosis. 3, 8, 9 The high frequency of TP53 mutations in EOC and the central role of p53 in regulating apoptosis suggest that it would be an appealing target for gene replacement therapy. 10 
Failure of p53 gene therapy
Based on the promising results from preclinical and phase I trials, 11, 12 a clinical trial of p53 gene-therapy was started for patients with primary stage III EOC with p53 mutations.
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For the patients in the experimental group, 5-day p53 gene therapy was added to the standard therapy of carboplatin and paclitaxel from the 2nd to 6th cycle. Each cycle consisted of intraperitoneal administration of 10 13 particles a day of replication-deficient wild-type p53 in a serotype-5 adenovirus. 10 However, the study was closed after the first interim analysis, which showed disappointing results. The addition of p53 gene therapy to standard treatment did not improve therapeutic effectiveness for patients with optimally debulked advanced EOC and actually increased treatment morbidity. 10 The plausible causes of the failure of the p53 gene-therapy study include inefficient vector system, neutralizing antiadenoviral antibodies in the ascitic fluid of patients, and the possibility of attenuation of the therapeutic effects of concomitantly administered cytotoxic drugs through the reactivated p53 pathways in tumor cells causing cell cycle arrest over cell death, and so forth. 13, 14 Despite the failure of trial, p53 is still a highly attractive In this review, we will mainly focus on DNA methylation and histone modifications in relation to chomoresistance in EOC.
P53-related epigenetic modulation and chemoresistance
Oshiro et al. demonstrated that mutation of p53 and 
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Adapted from Despierre et al. 15 and Zeller et al. 24 and updated with the most recent literature findings. NA, not applicable. (Table 1) . 23 There is growing evidence that epigenetic changes such as hypermethylation of CpG islands in promoter regions of tumor suppressor genes result in transcriptional silencing.
The hypermethylation of CpG islands is likely associated with the acquisition of drug resistance in EOC. 24 However, only 5% of genes with hypermethylation at their promoter region showed the downregulated level of expression in cisplatin-resistant A2780/cp70 cell lines. 24 Moreover, treatment of A2780/cp70 with the demethylating agent (decitabine) induced resensitization to cisplatin and re-expression of only 17% of the downregulated genes. Thus, less than 1% of hypermethylated genes in platinum-resistant ovarian cancer cells might account for the acquisition of platinum resistance. That is, only a small proportion of hypermethylated genes might be epigenetic drivers related to the chemoresistance, whereas almost all hypermethylated loci in ovarian tumors are likely to be bystanders. 16, 24 Zeller et al. identified consistent methylation and expression changes associated with chemoresistance.
MLH1
was shown to have a direct role in conferring cisplatin sensitivity when reintroduced into cells in vitro and considered as a potential key driver of chemoresistance whose expression is silenced by DNA methylation. In addition, a higher degree of CpG island methylation was associated with early disease recurrence after chemotherapy. 25 
Histone modification in ovarian cancer
Histone modifications are epigenetic changes that are involved in chromatin structure regulating the access to the underlying DNA. 30 More recently, Stronach et al. 31 showed HDAC4 mediated platinum resistance in ovarian cancer.
Significantly enhanced apoptotic response to platinum Adapted from Zeller et al. 34 with modification. DNMT, DNA methyltransferase; HDAC, histone deacetylase.
TCGA showed that 20% of studied high-grade serous ovarian cancer samples had germline or somatic mutations in BRCA1/2 and 11% lost BRCA1 expression through DNA methylation. Epigenetic silencing of BRCA1 was shown to be mutually exclusive of BRCA1/2 mutations. 33 In this study, there was no significant difference of survival between patients with epigenetically silenced BRCA1 and BRCA1/2 wild-type tumors. However, overall survival of the patients with BRCA1/2 wild-type tumors was worse than that of BRCA1/2 mutated tumors. Mutually exclusive genomic and epigenomic BRCA1 inactivation might explain different survival between the two groups.
Current status of epigenetic therapies in ovarian cancer
Based on the potential reversibility of various types of epigenetic changes, extensive preclinical and clinical studies have largely focused on two types of inhibitors: DNA methyltransferase inhibitors (DNMTIs) and histone deacetylase inhibitors (HDACIs) ( Table 2) . 34 
